RESUMEN
During the past 50 years, there have been more than 100 articles published in the Journal of Neuroscience Nursing covering the topic of neuro-oncology. This article will explore the historical implications and milestones from these articles. The analysis highlights the scope and depth of the many articles as they relate to the advancements in neuro-oncology.
Asunto(s)
Aniversarios y Eventos Especiales , Neoplasias Encefálicas/enfermería , Neoplasias Encefálicas/terapia , Enfermería en Neurociencias/historia , Enfermería Oncológica/historia , Neoplasias Encefálicas/historia , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Neurología/historiaAsunto(s)
Anciano , Prescripción Inadecuada , Personal de Enfermería en Hospital/organización & administración , Administración de la Seguridad/organización & administración , Gestión de la Calidad Total/organización & administración , Anciano/estadística & datos numéricos , Algoritmos , Revisión de la Utilización de Medicamentos/métodos , Enfermería Geriátrica/organización & administración , Hospitales Comunitarios , Humanos , Prescripción Inadecuada/efectos adversos , Prescripción Inadecuada/enfermería , Prescripción Inadecuada/estadística & datos numéricos , Conciliación de Medicamentos/métodos , Enfermeras Practicantes/organización & administración , Rol de la Enfermera , Investigación en Evaluación de Enfermería , Personal de Enfermería en Hospital/educación , Proyectos Piloto , Polifarmacia , Pautas de la Práctica en Medicina/estadística & datos numéricos , Comité de Profesionales/organización & administración , Evaluación de Programas y Proyectos de Salud , VirginiaRESUMEN
PURPOSE: Radiation Therapy Oncology Group (RTOG) 0118 randomized patients with multiple brain metastases to whole-brain radiotherapy (WBRT) +/- thalidomide. This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes. METHODS AND MATERIALS: Quality of life was determined with the Spitzer Quality of Life Index (SQLI). The Folstein Mini-Mental Status Exam (MMSE) assessed neurocognitive function. SQLI and MMSE were administered at baseline and at 2-month intervals. MMSE was scored with a threshold value associated with neurocognitive functioning (absolute cutoff level of 23) and with the use of corrections for age and educational level. RESULTS: Baseline SQLI predicted survival. Patients with SQLI of 7-10 vs. <7 had median survival time (MST) of 4.8 vs. 3.1 months, p = 0.05. Both arms showed steady neurocognitive declines, but SQLI scores remained stable. Higher levels of neurocognitive decline were observed with age and education-level corrections. Of patients considered baseline age/educational level neurocognitive failures, 32% died of intracranial progression. CONCLUSIONS: Quality of life and neuropsychological testing can be prospectively administered on a Phase III cooperative group trial. The MMSE should be evaluated with adjustments for age and educational level. Baseline SQLI is predictive of survival. Despite neurocognitive declines, QOL remained stable during treatment and follow-up. Poor neurocognitive function may predict clinical deterioration. Lack of an untreated control arm makes it difficult to determine the contribution of the respective interventions (i.e., WBRT, thalidomide) to neurocognitive decline. The RTOG has developed a trial to study the role of preventative strategies aimed at forestalling neurocognitive decline in this population.
Asunto(s)
Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/secundario , Trastornos del Conocimiento/etiología , Cognición/efectos de la radiación , Irradiación Craneana/efectos adversos , Calidad de Vida , Factores de Edad , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Trastornos del Conocimiento/diagnóstico , Escolaridad , Humanos , Escala del Estado Mental , Persona de Mediana Edad , Pruebas Neuropsicológicas , Estudios Prospectivos , Análisis de Supervivencia , Talidomida/uso terapéuticoRESUMEN
Ovarian cancer has nonspecific symptoms, and no screening tool is available for early diagnosis; therefore, only 19% of ovarian cancers are found at an early stage. Given the late diagnosis, women with ovarian cancer often have a prolonged course of treatment and significant morbidity that lasts into survivorship. However, distressing symptoms and their effects on quality of life have been relatively understudied, particularly in survivors of the disease. The purpose of this study was to describe a symptom cluster and its relationship to quality of life in women with ovarian cancer who were recruited from an online cancer support group. Descriptive statistics and hierarchical regression techniques were used to analyze the data obtained from a larger study testing the psychometric properties of a quality-of-life instrument. Most participants had stage III ovarian cancer, and nearly all (97%) had undergone treatment before the study. A symptom cluster composed of depression and fatigue was identified using work by Kim and colleagues [Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28(4):270-282]. The symptom cluster explained 41% (P = .000) of the variance in quality of life. These results suggest that fatigue and depression are significant problems for survivors of ovarian cancer.
Asunto(s)
Trastorno Depresivo/etiología , Fatiga/etiología , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/rehabilitación , Dolor/etiología , Calidad de Vida , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Análisis Multivariante , Neoplasias Ováricas/enfermería , Análisis de Regresión , Índice de Severidad de la Enfermedad , Sobrevivientes/psicologíaRESUMEN
PURPOSE: To describe the co-occurring symptoms (depression, fatigue, pain, sleep disturbance, and cognitive impairment), quality of life (QoL), and functional status in patients with high-grade glioma. DESIGN: Correlational, descriptive study of 73 participants with high-grade glioma in the U.S. METHODS: Nine brief measures were obtained with a mailed survey. Participants were recruited from the online message board of The Healing Exchange BRAIN TRUST, a nonprofit organization dedicated to improving quality of life for people with brain tumors. FINDINGS: Two symptom cluster models were examined. Four co-occurring symptoms were significantly correlated with each other and explained 29% of the variance in QoL: depression, fatigue, sleep disturbance, and cognitive impairment. Depression, fatigue, sleep disturbance, cognitive impairment, and pain were significantly correlated with each other and explained 62% of the variance in functional status. CONCLUSIONS: The interrelationships of the symptoms examined in this study and their relationships with QoL and functional status meet the criteria for defining a symptom cluster. The differences in the models of QoL and functional status indicates that symptom clusters may have unique characteristics in patients with gliomas.
Asunto(s)
Neoplasias Encefálicas/complicaciones , Trastornos del Conocimiento/etiología , Depresión/etiología , Fatiga/etiología , Glioma/complicaciones , Dolor/etiología , Trastornos del Sueño-Vigilia/etiología , Actividades Cotidianas/psicología , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Astrocitoma/complicaciones , Actitud Frente a la Salud , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/psicología , Análisis por Conglomerados , Trastornos del Conocimiento/epidemiología , Depresión/epidemiología , Fatiga/epidemiología , Femenino , Glioblastoma/complicaciones , Glioma/patología , Glioma/psicología , Estado de Salud , Humanos , Masculino , Persona de Mediana Edad , Investigación Metodológica en Enfermería , Dolor/epidemiología , Calidad de Vida/psicología , Índice de Severidad de la Enfermedad , Trastornos del Sueño-Vigilia/epidemiología , Encuestas y CuestionariosRESUMEN
PURPOSE/OBJECTIVES: To explore the prevalence and intensity of depression, fatigue, and pain in survivors of lung cancer; to examine the relationship of symptoms in a cluster; and to examine the relationship of the symptom cluster to quality of life (QOL). DESIGN: Secondary data analysis. SETTING: Online lung cancer support group. SAMPLE: 51 patients diagnosed with lung cancer. METHODS: Mailed survey with self-report of depression, fatigue, and pain measured by subscales of the Short-Form 36 Health Status Survey and QOL measured by the Fox Simple QOL Scale. Pearson's correlation and multiple regression analyses were used to examine the possible symptom cluster. MAIN RESEARCH VARIABLES: Depression, fatigue, pain, and QOL. FINDINGS: Depression, fatigue, and pain were found in a majority of survivors, with pain being the least common symptom. Fatigue was the most intense of the three symptoms. Two significantly correlated symptoms were depression and fatigue. The cluster explained 29% (p less than 0.01) of the variance in QOL in the lung cancer survivors. CONCLUSIONS: The data provided preliminary support for the presence of a symptom cluster in patients with lung cancer consisting of depression and fatigue. The cluster had a negative relationship with QOL. Survivors of lung cancer have depression and fatigue that affect QOL. IMPLICATIONS FOR NURSING: Healthcare providers must assess the potential for symptoms to cluster, adversely affecting key patient outcomes such as QOL. Through increased knowledge of symptom clusters, clinicians will be able to more effectively target the most distressing set of symptoms for intervention.
Asunto(s)
Depresión/etiología , Fatiga/etiología , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/psicología , Calidad de Vida , Sobrevivientes/psicología , Adulto , Anciano , Depresión/epidemiología , Fatiga/epidemiología , Femenino , Estado de Salud , Encuestas Epidemiológicas , Humanos , Masculino , Persona de Mediana Edad , Dolor/epidemiología , Dolor/etiología , PrevalenciaRESUMEN
Cognitive impairment is the most common neurologic problem associated with brain tumors and is present in many people with brain tumors from the time of diagnosis. Treatment of primary brain tumors with surgery, radiation, chemotherapy, and adjunctive medications such as corticosteroids results in further adverse effects on cognitive function. To plan the best care for patients with brain tumors, healthcare providers must initiate systematic and accurate assessment of cognitive functioning at the first clinic visit and extend assessment throughout the course of illness. This article outlines the range of cognitive dysfunction that may be seen in patients with primary brain tumors and offers information for clinicians seeking to develop their skills and implement a systematic approach to cognitive screening. The use of cognitive screening to guide timely intervention, such as referral to a neuropsychologist and the provision of anticipatory guidance to people with brain tumors and their families, is discussed.